| Document Date: 2014-01-22 14:37:27
Open Document File Size: 507,75 KBShare Result on Facebook
City Guangxi / Philadelphia / The Hague / Nashville / / Company Cummins / United States bBCS Consulting / Hartelust BV / PA cViroClinics Biosciences BV / Antiviral / aHemispherx Biopharma Inc. / / Continent Asia / / Country Netherlands / Vietnam / China / / Facility Newtown Square / III laboratory / The Netherlands Vanderbilt University / / IndustryTerm experimental protocol / vehicle citrate buffer control / food / buccal mucosal target site / treatment groups / citrate solution / / MedicalCondition inflammatory response / pulmonary protection / HPIV infection / resistant H7N9 influenza virus / primary atypical pneumonia / primary viral pneumonia / highly alveolar destructive primary viral pneumonia / antiviral and pulmonary protection / pulmonary cytokine storms / avian influenza virus / H5N1 infection / Human infection / severe acute respiratory syndrome / mixed inflammatory cells / primary viral atypical pneumonia / severe primary atypical pneumonia / marked inflammatory response / fibrinous pleuritis / influenza virus infections / severe viral primary atypical pneumonia / pulmonary emphysema / E. Slight interstitial inflammatory response / primary HPIVh pneumonia / influenza / adhesive fibrinous pleuritis / H1N1 influenza / pneumonia / Pulmonary photomicrographs / Mouse-Passaged Severe Acute Respiratory Syndrome / disease / pulmonary surface / highly pathogenic influenza virus / microscopic inflammatory response / SARS / post infection / acute respiratory distress syndrome / emphysema / seasonal and pandemic influenza / interstitial inflammation / alveolar epithelial necrosis / virus infection / pulmonary damage / influenza viruses / HPAI-H5N1 infection / Infection / Lethal Pulmonary Edema / pulmonary tissue / viral pneumonia / inflammation / influenza A/H5N1 / similar pulmonary pathologies16 / SARS/MERS viral infection / D. Moderate interstitial inflammatory response / / MedicalTreatment vaccination / Treatment protocol / / Organization Hemispherx Biopharma BOD / Vanderbilt University / Days Following Daily Alferon LDO Administration / / Person Caudal / / Position veterinarian / established nonhuman primate model for HPAI-H5N1 infection / independent member / representative / / Product Alferon N Injection / / ProvinceOrState ARDS / / Region Middle East / / Technology Methods Treatment protocol / experimental protocol / /
SocialTag |
Protection from the Pulmonary Tissue Damage Associated with Infection by H5N1 Highly Pathogenic Influenza Virus by Low Dose Natural Human IFN-a Administered to the Buccal Mucosa of Cynomolgus Monkeys a Strayer ,